Supplementary Appendix 1: Methods for measuring resource use and costs
To inform the economic analysis, data on primary care resource use (visits to the GP, practice nurse or other primary care staff), hospital-based resource use such as hospital emergency, outpatient visits, and inpatient stays, and the quantity of prednisolone consumed and other prescribed medication were recorded at each trial visit. These were grouped into four categories: primary care, secondary care, trial medication and prescribed medication use. Unit costs for all primary and secondary care resource use were obtained from the NHS Reference costs [1] and Unit Cost of Health and Social Care [2] ; and for prescription costs, obtained from the British National Formulary [3] . All costs were assessed in UK pounds sterling using the 2015 price level.
Supplementary Table 1 shows the various unit costs applied.
The primary care resource use captured information on the number of visits to the GP, practice nurse, or other primary care staff for each participant for the period between the data collection time points.
The total primary care cost was then assigned to each participant by multiplying the number of primary care visits with the primary care unit cost.
Hospital emergency and outpatient resource use were also reported as number of visits, and the total cost assigned to each participant was derived by multiplying the number of visits with the unit cost for each visit. For inpatient stays, the number of bed-days was defined as the interval between the admission and discharge date. Inpatient stays less than 24 hours were considered as zero-bed-days, and this incurred a single day-rate. In the NHS, a trim-point is the expected number of bed-days for an inpatient stay that is due to a specific cause [1] . All inpatient stays within the trim-point are priced at a flat rate. The trim-point for a paediatric renal-related inpatient stay is five bed-days. All inpatient stays up to five bed-days were priced at the appropriate flat rate. Inpatient stays beyond five bed-days incurred a day rate for excess bed-days beyond the trim-point.
The quantity of prednisolone consumed per participant was captured in milligrams, and the associated cost derived by multiplying the quantity by the unit cost for one milligram. Information on other prescribed medications, such as second line immunosuppressants, was captured as free-text on the case report form. Following the extraction of prescription data (the drug name and number of prescription days) from the free-texts, the medications were classified into thirty-one groups. An index drug was identified within each group onto which a daily unit cost was attached. For each drug, the number of prescription days was then multiplied by the daily unit cost for its group. The prescribed medication cost for each participant at every time-point was the total cost from all the 31 groups. 
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Supplementary Appendix 3: Methods for economic evaluation
The economic evaluation was undertaken from a health care perspective. It measured costs and effects at the end of 24 months and took the form of a cost-utility analysis, so compared the difference in costs and the difference in QALYs for the EC versus SC regimen.
QALYs were calculated from the generic preference-based CHU-9D [4] . Two approaches were used to construct QALYs according to the age group of the participants. For participants aged 5 years and older, utilities were estimated directly using the UK CHU-9D tariff [5] . For participants aged between two and four years, a crosswalk/mapping technique was applied using a published algorithm [6] . Unit costs for all primary and secondary care resource use were obtained from the NHS Reference costs [1] and Unit Cost of Health and Social Care [2] , and for prescription costs obtained from the British National Formulary (BNF) [3] ; and then applied to the resource use data collected at each trial visit. All costs were assessed in UK pounds sterling using the 2015 price level. For any missing data at each time point, multiple imputation was used to generate replacement values [7] .
To conduct the economic evaluation, costs and QALYs were adjusted for age and gender, plus baseline utility scores for QALY values, using a regression-based technique [8] . An incremental analysis was conducted according to the intention to treat principle [8] . The mean difference in cost was divided by the mean difference in QALYs, to produce an incremental cost-effectiveness ratio (ICER), and therefore the cost per additional QALY gained for having EC versus SC. A 3.5% discount rate was applied to both costs and QALYs.
To estimate the uncertainty around the ICER, a probabilistic sensitivity analysis was conducted. This was done using a method called bootstrapping which empirically constructs the distribution of cost-effectiveness ratios by producing 5000 paired cost/QALY estimates.
Bootstrapping adequately captures the variability within the cost per QALY pairs as it graphically represents the distribution across both the positive (cost-incurring or QALYgaining) and negative (cost-saving or QALY losing) spheres. The bootstrapped pairs of mean costs and QALYs were graphically presented on a cost-effectiveness plane, and a costeffectiveness acceptability curve (CEAC) constructed from the plotted points using the net monetary benefit approach [9] [10] . This CEAC shows the probability of EC being cost-effective at different cost per QALY thresholds. In the UK, interventions are considered cost-effective if the cost per additional QALY gained is less than a threshold value of £20,000 [11. A series of sensitivity analyses were conducted to assess the robustness of the results to the assumptions made and are described in full within supplementary appendix 5.
Supplementary appendix 4: Results of economic evaluation
The mean cost per participant was £2,696 and £4,369 for the EC and SC groups respectively Adjusted mean values were obtained from the multiple regression equations that have controlled for baseline age and gender.
Complete cases were participants who returned trial questionnaires.
CI= Confidence Interval; EC=Extended group; SC=Standard group; SD= Standard Deviation; SE= Standard Error. When the cost and QALY differences were combined, they showed that EC was dominant as it was cheaper and produced a gain in QALYs compared to SC. ICERs were not calculated as This result was subject to a series of sensitivity analysis -see Supplementary Appendix 5. The EC arm remained the dominant strategy when the analysis was conducted again using complete-case analysis; and for subgroup analysis by ethnicity, and by age group from splitting the trial population into participants older and younger than 5 years. Furthermore, a post-hoc sensitivity analysis was conducted to exclude participants with total costs that were considered markedly higher when compared to the mean total cost as the presence of cost outliers can influence missing data multiple imputation. One participant within the SC arm was admitted to hospital for 214 days on account of complications related to nephrotic syndrome, which markedly increased the mean total cost for the SC group. Excluding this participant reduced the mean cost for the SC group to £3,260. However, even after this exclusion, EC remained the dominant strategy and, assuming that society is willing to pay £20,000 for a QALY gain, the revised probability of EC being cost-effective remained high at 96%. 
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